GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervasive, and debilitating symptoms1,2,3

Patients experience high rates of pharmacotherapy switching, discontinuation, and prolonged gaps in care4

Wired for WorryTM addresses the urgent need for greater understanding of GAD by equipping healthcare providers with education on its symptoms, lifelong impact, and underlying neurobiology

Definium Therapeutics, Inc. ("Definium" or the "Company"),a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the launch of Wired for Worry, a new healthcare provider disease education initiative focused on generalized anxiety disorder (GAD).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.